When Cancer Care Advances, Education Must Advance Too

One lesson has stayed with me throughout my career in commercial oncology: scientific progress only makes a difference when it reaches the people who need it. As cancer care becomes more personalized and complex, bringing new options to patients depends on more than the science alone.

This November, Lung Cancer Awareness Month and Gastric Cancer Awareness Month bring attention to two distinct cancer communities. While these diseases are different, they share an increasingly important reality: as cancer care evolves, patients, caregivers and healthcare professionals need both meaningful treatment options and timely, understandable information to help navigate the changing treatment landscape.

That information may help someone understand a diagnosis, prepare for an appointment or find support at a difficult moment. It can also make hope feel more tangible by giving people something concrete to ask about or act on.

In gastric cancer, the need for better options from the start of treatment is especially clear. Many people with gastroesophageal adenocarcinoma, or GEA, are diagnosed after the disease has already advanced, which makes the first treatment decision an important one. That is why progress in first-line care matters so much to patients and the physicians who treat them. Biomarker testing is part of how that progress reaches the right patients. For people with advanced GEA, HER2 testing can identify whether a tumor is HER2+. Knowing that status may help determine whether a HER2-targeted treatment approach could be appropriate.

Receiving a result does not necessarily mean understanding it. For many people, understanding biomarker testing is one more challenge during an already overwhelming time. People should feel comfortable asking whether their tumor has been tested, what the result means and how it could affect their options. Their healthcare teams play an essential role in helping them make sense of the answers.

A new educational website for US healthcare professionals, Shining Hope in Gastric, provides information about gastric cancers and HER2 testing to support those discussions.

The need for clear information extends beyond testing and treatment decisions. Across cancer types, people also need support that helps them navigate the day-to-day realities of living with a diagnosis. That is especially true in small cell lung cancer, where patients and caregivers often face difficult questions shortly after diagnosis.

Nothing Small About It is one resource developed for people diagnosed with small cell lung cancer and their caregivers. The site includes information about diagnosis, treatment and support while keeping the person behind the diagnosis in view.

Bringing treatment advances to patients starts with listening to the people closest to care. Healthcare professionals can help us understand where barriers to care exist and where conversations become difficult. People living with cancer and their families can show us where information is unclear or support is missing.

Whether someone is seeking to better understand a biomarker result, connect with other patients or find practical support, advocacy organizations often serve as a trusted starting point. They help families find answers, connect with support and make their voices heard. Awareness months are a chance to recognize that work and give these communities greater visibility.

Awareness months help bring visibility to important diseases, but the work of bringing progress to patients continues year-round. As science advances and care becomes increasingly personalized, ensuring new options reach the people who may benefit, and that they have access to understandable, actionable information will remain essential. While information cannot remove the uncertainty that often accompanies cancer, it can help patients, caregivers, and healthcare professionals approach important conversations with greater confidence. I have learned not to underestimate what those conversations can change.